Brain-Derived Neurotropic Factor in Neurodegenerative Disorders

Ibrahim, Abdallah Mohammad; Chauhan, Lalita; Bhardwaj, None Aditi; Sharma, Avadhesh C.; Fayaz, Faizana; Kumar, Bhumika; Alhashmi, Mohamed; Alhajri, Noora; Alam, Md Sabir; Pottoo, Faheem Hyder

doi:10.3390/biomedicines10051143

Cited by 40 publications

(15 citation statements)

References 162 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the combination treatment of baicalein and memantine at the dose of 20 + 5 mg/kg augmented neuronal health, which can be confirmed by the brown colouration of moderate expression of BDNF. Similarly the combination treatment of baicalein with memantine at a dose of 20 + 10 mg/kg also demonstrated significant enhancement in neuronal survival and plasticity depicted by the dark brown colouration of moderate BDNF expression in both the hippocampus and cortex [ 34 ]. The OD data plotted against treatment group also demonstrated the highest OD for the combination treatment of baicalein and memantine at the dose of 20 + 10 mg/kg when compared with the disease control group ( Figure 12 and Figure 13 ).…”

Section: Resultsmentioning

confidence: 99%

The Combination of Baicalein and Memantine Reduces Oxidative Stress and Protects against β-amyloid-Induced Alzheimer’s Disease in Rat Model

Jadhav

Kulkarni

2023

Antioxidants

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neuronal condition causing progressive loss of memory and cognitive dysfunction particularly in elders. An upsurge in the global old age population has led to a proportionate increase in the prevalence of AD. The current treatments for AD are symptomatic and have debilitating side effects. A literature review and current research have directed scientists to explore natural products with better safety and efficacy profiles as new treatment options for AD. Baicalein, belonging to the flavone subclass of flavonoids, has been reported for its anti-oxidant, anti-inflammatory, AChE enzyme inhibitory activity and anti-amyloid protein aggregation activity, which collectively demonstrates its benefits as a neuroprotective agent. Presently, memantine, a NMDAR antagonist, is one of the important drugs used for treatment of Alzheimer’s disease. The current study aims to investigate the effect of baicalein in combination with memantine in β-amyloid-induced AD in albino Wistar rats. Baicalein (10 mg/kg) alone, 5 mg/kg and 10 mg/kg in combination with memantine (20 mg/kg) was administered for 21 days. Treatment with baicalein in combination with memantine showed significant improvement in behavioural studies. The combination treatment decreased oxidative stress, β-amyloid plaque formation and increased the expression of brain-derived neurotrophic factor (BDNF) in the brain. From the results, it can be concluded that treatment with baicalein and memantine could be beneficial for reducing the progression of neurodegeneration in rats. Baicalein has an additive effect in combination with memantine, making it a potential option for the treatment of AD.

show abstract

Section: Resultsmentioning

confidence: 99%

The Combination of Baicalein and Memantine Reduces Oxidative Stress and Protects against β-amyloid-Induced Alzheimer’s Disease in Rat Model

Jadhav

Kulkarni

2023

Antioxidants

View full text Add to dashboard Cite

show abstract

“…But of course, because of the small size and non-peptide nature they can lead to the development of molecule that can follow an alternate route with fewer side effects and more specific to the receptor [215][216][217][218][219][220][221]. In recent years, lots of review and research have been published on recent advancements of nanotechnology and their application on neurological disease as well as NP [222][223][224][225][226][227][228][229][230][231][232][233].…”

Section: Mechanism For Excitatory Effect Of Drugsmentioning

confidence: 99%

N-type calcium channel blockers: a new approach towards the treatment of chronic neuropathic pain

Choudhary

Kaur

Waziri

et al. 2023

Exploration of Medicine

Self Cite

View full text Add to dashboard Cite

Neuropathic pain (NP) remains maltreated for a wide number of patients by the currently available treatments and little research has been done in finding new drugs for treating NP. Ziconotide (PrialtTM) had been developed as the new drug, which belongs to the class of ω-conotoxin MVIIA. It inhibits N-type calcium channels. Ziconotide is under the last phase of the clinical trial, a new non-narcotic drug for the management of NP. Synthetically it has shown the similarities with ω-conotoxin MVIIA, a constituent of poison found in fish hunting snails (Conus magus). Ziconotide acts by selectively blocking neural N-type voltage-sensitized Ca2+ channels (NVSCCs). Certain herbal drugs also have been studied but no clinical result is there and the study is only limited to preclinical data. This review emphasizes the N-type calcium channel inhibitors, and their mechanisms for blocking calcium channels with their remedial prospects for treating chronic NP.

show abstract

“…Long-term synaptic plasticity was identified first by Timothy Bliss and TerjeLomo. When the post-tetanic potentiation lasts for days, due to repeated synaptic activity strengthening of synapses occurs, this is otherwise called as LTP [ 22 ]. This is associated with increased influx of Ca 2+ in the post-synaptic terminal [ 23 ] which increases the synaptic strength.…”

Section: Synaptic Neural Plasticitymentioning

confidence: 99%